Arvinas Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arvinas wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Arvinas is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Arvinas.

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Monday, May, 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.01. Arvinas had a negative trailing twelve-month return on equity of 33.38% and a negative net margin of 656.61%.
View Arvinas' earnings history.

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARVN shares have increased by 68.7% and is now trading at $74.34.
View which stocks have been most impacted by COVID-19.

12 brokerages have issued 1 year price objectives for Arvinas' shares. Their forecasts range from $93.00 to $150.00. On average, they expect Arvinas' stock price to reach $119.15 in the next year. This suggests a possible upside of 60.3% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Some companies that are related to Arvinas include Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Maravai LifeSciences (MRVI), Teva Pharmaceutical Industries (TEVA), Ono Pharmaceutical (OPHLF), CureVac (CVAC), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY) and Ultragenyx Pharmaceutical (RARE).
View all of ARVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.13%), Price T Rowe Associates Inc. MD (4.87%), Bellevue Group AG (4.23%), JPMorgan Chase & Co. (3.53%), RTW Investments LP (3.31%) and Gilder Gagnon Howe & Co. LLC (3.24%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Gilder Gagnon Howe & Co. LLC, Millennium Management LLC, Ikarian Capital LLC, Rock Springs Capital Management LP, Bellevue Group AG, Voloridge Investment Management LLC, and Sectoral Asset Management Inc. Company insiders that have sold Arvinas company stock in the last year include Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas or view top insider-selling stocks.

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., EcoR1 Capital LLC, Wasatch Advisors Inc., BlackRock Inc., Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, JPMorgan Chase & Co., and Morgan Stanley. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or or view top insider-buying stocks.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $74.34.

Arvinas has a market capitalization of $3.64 billion and generates $21.80 million in revenue each year. The company earns $-119,330,000.00 in net income (profit) each year or ($3.02) on an earnings per share basis.

Arvinas employs 179 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected]